Search
for
Sort by
Research 31–60 of 77
- Retrospective Comparison of Inflammatory Markers in Severe Acne Vulgaris Patients and Normal Population
- Hair Changes due to Drugs
- ESGCT and FSGT Collaborative Congress Helsinki, Finland September 17–20, 2015 Abstracts
- Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Axitinib-induced repigmentation of grey hair in a patient with metastatic renal cell carcinoma
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Identification and characterization of Birt–Hogg–Dubé associated renal carcinoma
- Nilotinib-Induced Keratosis Pilaris
- Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning
- Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors
- A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
- Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
- 7410 Bevacizumab Induced Hypothyroidism
- Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
- Dissecting the genetic variations associated with response to first-line chemotherapy in patients with small cell lung cancer: a retrospective cohort study
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies
- Tumor Angiogenesis and Anti-angiogenic Therapy
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- 9-cis-Retinoic Acid Capsules in the Treatment of AIDS-Related Kaposi Sarcoma
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Persistent hair growth during treatment with the EGFR inhibitor erlotinib
- Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022
- Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
- Merkel cell carcinoma: updates in tumor biology, emerging therapies, and preclinical models
- Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer
- Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024